The purpose of this study was to investigate the comparative efficacy and safety of equal doses of inhaled fluticasone propionate (FP) and inhaled budesonide (BUD) using their respective dry powder inhalers in a population of severe asthmatics requiring high doses of inhaled corticosteroid. This double-blind double-dummy parallel-group study compared the effects of 24 weeks of treatment with FP (2000 pg daily via a Diskhaler@ inhaler; Glaxo Wellcome, Evreux, France) and BUD (2000 pg daily via a Turbuhale?
Introduction
The comparative therapeutic profiles of fluticasone propionate (FP) and budesonide (BUD) in asthma patients, administered by either metered-dose inhalers (MDIs) or dry powder inhalers (DPIs), have been established in numerous clinical trials in which efficacy (measured by peak expiratory flow; PEF) and safety (measured by morning Paper received 18 November 1998 and accepted in revised form 20 April 1999. Correspondence should be addressed to: Dr J. H. Heinig. Rigshospitalet, RHIMA Centret, Afd, TA (Medicinsk), 2200 Copenhagen N, Denmark. Fax: 145 35 457583.
0954-6111/99/090613+08 $12.00/O serum cortisol level) have been compared within studies. In two separate studies involving patients with mild/moderate asthma (1, 2) increasing the daily dose of FP from 100 pg up to 800 ,ug produced a significant dose-related increase in both morning and evening PEF. In an attempt to obtain an overview of the comparative efficacy and safety of FP, BUD and BDP, a meta-analysis (3) of all trials directly comparing FP and BUD (1, 4, (5) (6) (7) (8) (9) , and FP and BDP (2, (10) (11) (12) (13) (14) (15) , in which morning peak flow was an outcome measure and drugs were compared at the 2: 1 dose ratio, has been performed. The meta-analysis found the pooled value of the mean morning PEF to be significantly higher with FP than with a dose of BUD of at least twice the,FP dose (3). Also, across five studies, the pooled value qf plasma cortisol level following FP was significantly greater than that following BUD (3). In the studies comparing FP at half the dose to BDP, the pooled analysis of improvement in mean morning PEF showed a non-significant trend in favour of FP and there was no significant difference between FP and BDP in plasma cortisol levels (3).
In a study of patients with severe asthma, the mean serum cortisol increased in patients treated with FP 1000 pg daily, while it was reduced in patients treated with BDP 2000 vg daily, suggesting an increased therapeutic benefit in favour of FP (10) . In similar studies involving patients with severe asthma, no statistically significant suppression of serum cortisol levels was observed following administration with FP and BDP both at 1500 ,ug daily (16) and the suppression of serum cortisol levels observed with FP 1000 pg was less than the suppression seen with BUD 1600 /Lg (17) .
Both FP and BUD are commercially available as dry powder formulations; it has been established that FP is equally safe and effective when administered by either MD1 or DPI (l&20), but the deposition of BUD is greater when administered as a dry powder than via its MD1 (21) . The purpose of this study was to investigate the comparative efficacy and safety of equal doses of FP and BUD in a population of severe asthmatics requiring high doses of inhaled corticosteroid. The study used the highest recommended dose of FP which has been shown in previous studies to have a favourable risk: benefit ratio (17, (22) (23) (24) (25) (26) . The study gave particular emphasis to the incidence and severity of asthma exacerbations, which can be considered to be a clinically relevant end-point in this population of patients. This study is the first in which a specifically designed module was used to collect information on asthma exacerbations.
Methods

STUDY DESIGN
This double-blind, double-dummy, parallel-group study was conducted in 47 centres in four different countries (Belgium, Canada, Denmark, The Netherlands): and consisted of a 2-week run-in period, a 24-week treatment period with either FP or BUD 2000 yg daily, and a 2-week follow-up period. The study was conducted in accordance with the Declaration of Helsinki and its amendments, and conformed to good clinical practice. The local medical ethics committee at each centre approved the protocol for the study.
PATIENTS
Symptomatic patients, aged IS-75 years, with a documented history of (in the previous 12 months), or pre-study evidence of, reversible airways disease [change in forced expiratory volume in 1 set (FEVi) > 15% in the 15 min following administration of salbutamol 400 or 800 pg]> requiring or responding to treatment with inhaled BDP or BUD 1500-2000 pg daily or FP 750-1000 pg daily, were considered for enrolment into the study. Patients with serious uncontrolled systemic disease (including bone disease) at the start of the run-in period, and patients who had required treatment with oral steroids or were being treated with research medication within 1 month of the start of the run-in period, were not considered eligible for the study. Pregnant and lactating women were also not eligible. The aim of the study and a detailed explanation of the patient's involvement in the study (including the decision by the patient to withdraw for any reason) were provided by the investigator before patients gave written informed consent to participate in the study.
RUN-IN PERIOD
Patients continued their existing medication throughout the run-in period with the exception that the only permissible inhaled bronchodilator was salbutamol, which was to be used on an 'as required' basis to relieve symptoms of reversible airways obstruction. Each day the patient completed a diary card with respect to morning and evening peak expiratory flow (PEF; highest of three consecutive readings), severity of daytime (score of O-5) and night-time (score of O-4) asthma symptoms and number of doses of inhaled salbutamol used. At the end of the run-in period the reversibility challenge to salbutamol was repeated and patients were allocated to study treatment if: there was demonstrable reversible airways disease; their mean morning PEF during the last 7 days of the run-in period was <85% of the post-salbutamol challenge PEF; the mean daytime symptom score was 22 on at least 7 days during the run-in period; and the investigator was satisfied that the patient was able to use the Diskhaler@ and Turbuhalera correctly.
TREATMENT PERIOD
Patients were randomly allocated to treatment with either FP 1000 pg twice daily or BUD 1200 pg in the mornings and 800 pg in the evenings. Patients were also provided with placebo inhalers of the alternative device in order to maintain blinding. During the 24-week treatment period patients were permitted to take methylxanthines, anticholinergics, nedocromil, sodium cromoglycate, ketotifen and long-acting P-agonists on the understanding that the dose remained unchanged during the study. Intranasal corticosteroids were permissible within the recommended dose-range for the particular preparation, as was the administration of anti-fungal lozenges for the treatment of oropharyngeal candidiasis. Full details of concomitant medication (including changes in dose) were recorded at each study visit. Patients completed the diary card each day, and attended the clinic every 4 weeks during the first 8 weeks of treatment and then every 8 weeks. At these clinic visits patients' FEVl, forced vital capacity (FVC) and PEF were measured and recorded. There was a 2-week follow-up period either at the end of the treatment period or after withdrawal of the patient from the study. At a clinic visit at the end of this period FEVr, FVC and PEF were recorded, but no diary card was completed between the end of the treatment period and this follow-up visit.
EXACERBATIONS
Patients who experienced worsening asthma symptoms were asked to increase their use of rescue salbutamol in an attempt to obtain symptomatic relief, contact the investigator, general practitioner or primary care physician, report to the clinic within 24 h of the onset of exacerbations and record their symptom score, PEF and bronchodilator usage on their diary cards. The investigator decided whether or not to initiate treatment with oral steroids. The dose of oral steroid was only reduced when there was clinical evidence that their reversible airways disease was under control. If it was not possible to reduce the dose of oral steroid over 3 weeks the patient was withdrawn from the study. All data involving the exacerbation, its severity, type of action taken, days absent from work and the PEF during the exacerbation were recorded on a specifically designed module in the case record form.
SAFETY
Blood samples for routine haematology, biochemistry, markers of bone turnover and serum cortisol levels, and urine for routine urinanalysis were taken (between 0800 and 1000 h) from fasting patients at the pre-study visit, at the end of treatment (irrespective of when this occurred) and at the follow-up visit if haematological and biochemical values were abnormal at the end of treatment. Blood samples were also taken for markers of bone turn-over (calcium, collagen and osteocalcin) and serum cortisol every 4 weeks during the treatment period. Adverse events, including acute exacerbations, were recorded daily in the diary card by each patient and at every clinic visit on the case record form by the investigator.
STATISTICAL ANALYSIS
The sample size calculation required 189 patients in each treatment group, based on a 90% power to detect a difference equal or greater than 15 1 min-' in PEF. The trial analysis was conducted on an intent-to-treat basis and included all patients randomized to treatment. All analyses were two-sided at the 5% significance level and no adjustments were made for multiple testing. Variables on an interval or ratio scale were analysed using analysis of covariance with the baseline measurement as the covariate. Variables, where appropriate, were log-transformed to satisfy distributional assumptions for parametric tests and for variables on the ordinal scale the absolute change from baseline was analysed using the Wilcoxon rank sum test. All data were analysed using SPSSWIN software (SPSS Inc., Chicago, IL, U.S.A.), version 6.1.2, and for data not subject to statistical analysis, e.g. markers of bone turnover, only descriptive analyses were conducted. Adverse events were coded by body system in accordance with WHO criteria.
Mean morning and evening PEF, daytime and night-time symptom scores and percentage symptom-free days and nights were computed overall and for weeks 14, 5-8, 9-16 and 17-24. Treatment effect on PEF was calculated as the mean difference between treatments adjusted for the differences in baseline PEF and the 95% confidence limits. The treatment effect was tested for significance by ANOVA with the mean run-in PEF as covariate and included countries as factors in the model. The effect of treatments on daytime and night-time symptom score were analysed using the Wilcoxon rank-sum test for the median symptom scores, the change in median symptom scores from baseline and the percentage symptom-free day and nights. The difference in the need for rescue medication was analysed by comparing the percentage rescue-free nights and days using ANOVA with baseline measurements as covariate. The significance of the effect of treatment on FEVi, FVC and PEF at each visit was analysed using ANOVA models with the end of run-in values as covariate and country as factor.
The incidence of exacerbations was obtained from four sources; the acute exacerbation module in the case record form, the response to a 'yes/no' question at each clinic visit, the diary card and the adverse event section in the case record form. All sections were subjected to thorough crosschecking. The definition of asthma exacerbation when completing the exacerbation module was at the discretion of the investigator. The definition of asthma exacerbation from the adverse events section of the case record form was taken as anything referring to asthma. This resulted in some discrepancy between the two sections that could not be completely reconciled retrospectively. In view of the lack of experience with the exacerbation module, not all the statistical analyses performed had been pre-defined in the protocol, but they were undertaken to further explore this important component .of asthma control. The statistical analysis was as follows: Fisher's exact test to compare the number of patients who had more than one exacerbation; actuarial survival analysis techniques to determine time to first exacerbation and exacerbation-free time; Wilcoxon statistics to compare disease-free distributions and ANO-VA to compare the mean lowest PEF during exacerbation using mean daily-run-in PEF as covariate and country as factor. Serial serum cortisol levels were compared using ANOVA with country as factor and baseline cortisol measurements as covariate, and the incidence of adverse events was compared using Fisher's exact test.
Results
A total of 548 patients entered the run-in period, of which 395 were randomized to treatment with either FP or BUD. The majority of patients who withdrew during the run-in period did so because they did not fulfil the run-in criteria (67%). Other reasons (patients could withdraw for more than one reason) were lack of efficacy (lo/u), adverse events (9%) failure to return (9%) and other (17%). The two treatment groups were well matched for all aspects of FEVi, forced expiratory volume in 1 set; FVC, forced vital capacity; PEF, peak expiratory flow rate.
demography, clinical history, pre-treatment lung function and response to challenge with inhaled salbutamol (Table 1) . The adjusted mean differences between the two treatments with respect to FEVi, FVC and PEF measured at each visit were in favour of FP throughout the treatment period and the difference reached statistical significance for FEVi at weeks 5-8 (0.09 1; P = 0.04), 9-16 (0.10 1; P = 0.03) and 17-24 (0.12 1; P = 0.02). Although there was no significant difference between the two treatments on morning and evening PEF, the adjusted mean PEF was consistently higher both overall and for each treatment period for patients treated with FP (Fig. 1) . In addition, the upper 95% confidence limits indicated that the FP-BUD difference in PEF exceeded 15 1 min-' both overall and for each time segment following 4 weeks treatment for morning PEF, and for weeks 9-16 and 17-24 for evening PEF ( Table 2) .
The difference in mean morning PEF on the last 7 days of treatment relative to the last 7 days of the run-in expressed as % predicted PEF was classified according to those patients with clinically relevant changes. An important increase in PEF was classified as an increase of more than lo%, a mild increase as a less than 10% increase, a mild decrease as between 0 and 10% and an important decrease in PEF as a decrease of 10% or more. When looking at the response to treatment in this way, there was a patients treated with BUD were more likely to experience an important decrease in PEF than those treated with FP (Table 3) . These preferential effects in favour of FP were confirmed by statistically significant changes in other clinical parameters. There was a statistically significant treatment effect in favour of FP on the median daytime symptom scores for weeks 5-8 (P = 0.05) and 9-16 (P = 0.01). The adjusted mean percentage symptom-free days (31.5% on FP and 22.8% on BUD) also reached statistical significance overall (P = 0.02) and during weeks 17-24 (P = 0.02). During each treatment period the difference in percentage rescuefree days (42.7% FP vs. 33.7% BUD) reached statistical significance overall (P = O-02) and during weeks 17-24 (P = 0.02).
There was no significant difference between the two treatments with respect to the number of patients with one or more exacerbations (Table 4 ). The number of exacerbations recorded in the exacerbation-specific module in the case record form was 203, 113 (33.8% of patients) in the FP group and 90 (28.4% of patients) in the BUD group, there being no significant difference between the two treatments. The majority of exacerbations (85% in the FP group and 83% in the BUD group) required only one of the actions described in Table 5 . The percentages of patients treated with FP and BUD who remained exacerbation-free after 180 days were 60 and 68%, respectively, and there was no statistical difference in this distribution. The mean time to resolution of an exacerbation was, however, less in the FP compared with the BUD group (11.0 vs. 14.7 days; P = 0*035), and the mean duration of all exacerbations (for an individual patient) was shorter (18.5 vs. 23.6 days; P = 0.12). In addition, the number of days absent from "Denotes any combination of management at home, visit to GP surgery, hospital outpatient or hospital inpatient.
work was lower in FP-treated patients (P = 0.012) compared with those receiving BUD (Fig. 2) , and the lowest PEF recorded during an exacerbation was higher in the FP group compared with the BUD group (301.7 and 263.7 1 min-', respectively; P = 0.07).
At these microgram equivalent doses of FP and BUD no difference in the systemic corticosteroid effect was observed. The pre-treatment serum cortisol levels for FP and BUD were 356.7 (SD 192. 3) and 380.5 (SD 231.7) nmol 1-I respectively, and these decreased over the treatment period by 16.7% for patients receiving FP and by 13.9% for those receiving BUD (P = 0.43). After 24 weeks of treatment the mean cortisol levels were 285.5 (SD 189.4) and 315.0 (SD 184.3) mmol 1-l with FP and BUD, respectively.
In addition, there was no significant effect of either corticosteroid on any of the markers of bone turn-over during the treatment period. Calcium levels were stable during FP and BUD treatment, remaining close to the pretreatment values of 41.54 and 41.32 ng ml-', respectively. Collagen levels increased slowly but consistently over the 24-week treatment period from 91.91 to 107.05 pg 1-l in the FP-treated group, and from 98.01 to 113.74 pg 1-l in the BUD-treated group. Osteocalcin levels decreased slowly but consistently from 4.90 to 4.19 ng ml-' in patients receiving FP and from 5.17 to 4.27 ng ml-' in those receiving BUD.
The number of adverse events reported, the number of patients with one or more events (78% for FP and 77% for BUD) and the most frequently occurring events (Table 6) were equally distributed between the two treatment groups. 
Discussion
The results of this study indicate that FP, at a dose of 2000 ,ug daily, produced preferential changes in lung function and decreased the severity of exacerbations compared with BUD at the same dosage. This was achieved without producing any greater systemic adverse effect than BUD. Neither drug had an effect on markers of bone turnover or clinically relevant effects on serum cortisol levels. The inclusion and exclusion criteria to the study probably resulted in the exclusion of the patients who would have benefited most from the treatments in this study. Even though the study only recruited patients who, in the opinion of the investigator, were appropriate for treatment with these doses of inhaled corticosteroid, the exclusion criteria meant that those patients who experienced frequent exacerbations were excluded. This resulted in patients with more moderate asthma being treated in the study and this is reflected in the baseline lung function scores. Consequently, it is likely that the patients had not required such high doses of corticosteroid and both treatments could be considered to be on or near the plateau of the patient's corticosteroid dose-response curve for PEF (27) . It is possible, however, that the corticosteroid doseresponse curve is different for each individual characteristic of asthma control (28) and this is why treatment with the more potent corticosteroid, FP, resulted in significantly better improvements in some aspects of asthma control relative to BUD.
corticosteroid. This is relevant because it has been shown that the systemic absorption of FP from the lungs is greater in healthy volunteers than in patients with asthma (29) . The reason for this is because a greater proportion of the inhaled dose reaches the site of absorption (the alveoli) rather than the site of action (the bronchioles). Similarly, for a given dose of FP greater systemic absorption would be expected in patients with moderate asthma relative to patients with severe asthma. In addition to drug deposition in the lungs being affected by the severity of asthma, there are considerable differences in drug delivery to the lungs between inhalation devices (30) , and the dependence of these devices on inhalation flow rates (31) . It is therefore not advised to extrapolate the results of lung deposition studies to other drugs in either the same device or different devices (32) .
Overall, therefore, at equal doses FP is more effective than BUD at producing clinically relevant improvements in lung function and in reducing the daytime asthma symptom score in patients with severe asthma. There was no overall difference in the number of exacerbations between the two treatment groups, but patients treated with FP experienced less severe asthma exacerbations (seen as time to resolution of an exacerbation and time absent from work) than those receiving BUD. This may have important pharmacoeconomic benefits for FP and warrants further investigation. Both treatments were well tolerated. In retrospect, the patients recruited into this study probably had no need for such high doses of inhaled corticosteroid but, irrespective of this, FP at microgram equivalent doses showed evidence of superior efficacy to BUD with respect to lung function and severity of asthma exacerbations without producing any greater adverse systemic effect.
